PLS1: A Drug Target / Disease Biomarker (G5357)

Target Name: PLS1

NCBI ID: G5357

PLS1

PLS1: A Drug Target / Disease Biomarker

PLS1 (Proteasome-Mediated Protein Degradation 1) is a protein that is expressed in a variety of tissues throughout the body. It is involved in the degradation of a wide variety of proteins, including those that are involved in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. As a result, PLS1 has been identified as a potential drug target or biomarker for a variety of diseases.

One of the key features of PLS1 is its role in the degradation of proteins. PLS1 is a component of the proteasome, a complex of proteins that helps to break down and remove damaged or unnecessary proteins from the body. When a protein is targeted for degradation by the proteasome, PLS1 helps to facilitate the process by interacting with the proteasome and participating in the formation of a so-called grade-dependent structure on the protein surface. This structure is thought to play a key role in determining which proteins are targeted for degradation by the proteasome.

PLS1's involvement in protein degradation is also of interest in the context of disease. Many diseases are characterized by the build-up of abnormal or misfolded proteins that can cause a variety of problems, including the development of neurodegenerative diseases, cancer, and autoimmune disorders. By helping to remove damaged or unnecessary proteins from the body, PLS1 may be a potential target for therapies aimed at reducing the production and accumulation of these misfolded proteins.

Another potential aspect of PLS1 is its role in the regulation of cellular processes. PLS1 is involved in a variety of cellular processes, including cell signaling, cell adhesion, and the regulation of inflammation. Its expression has been shown to be regulated by a variety of factors, including cytokines, growth factors, and chemokines. This regulation suggests that PLS1 may play a role in the complex interplay between cells and their environment.

PLS1's potential as a drug target or biomarker is further demonstrated by its expression in a variety of disease-prone organisms, including humans. For example, PLS1 has been shown to be overexpressed in a variety of cancer tissues, and may contribute to the development and progression of these diseases. Additionally, PLS1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, PLS1 is a protein that is expressed in a variety of tissues throughout the body and is involved in the degradation of proteins, as well as the regulation of cellular processes. Its expression has been shown to be regulated by a variety of factors, including cytokines, and it is involved in the development and progression of a variety of diseases. As a result, PLS1 is a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective therapies aimed at reducing its expression or activity.

Protein Name: Plastin 1

Functions: Actin-bundling protein. In the inner ear, it is required for stereocilia formation. Mediates liquid packing of actin filaments that is necessary for stereocilia to grow to their proper dimensions

The "PLS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets